EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte Studie

Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double‐peak absorption profile after oral administration to human volunteers

Sally A Helmy

Biopharmaceutics & Drug Disposition · 2013-07 · 34 (5) · 288-301

DOI: 10.1002/bdd.1843 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Biopharmaceutics & Drug Disposition, online erschienen am 19.05.2013. Verfasst von Sally A Helmy. Beteiligte Einrichtung: Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt. Sallyhelmy@yahoo.com. Hauptthemen laut MEDLINE: Sulpiride. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The pharmacokinetics of oral drugs that exhibit double peaks cannot be described adequately by using conventional compartmental models.

Objective

The aim of this study was to describe the double‐peak plasma pharmacokinetic profile of sulpiride after oral administration to healthy volunteers based on physiological and biopharmaceutical considerations.

Methods

A single 100 mg dose of sulpiride was given to 16 healthy volunteers. Blood samples were drawn at different times and analysed by a validated HPLC assay method. Plasma profiles were evaluated by non‐compartmental and compartmental approaches.

Results

The non‐compartmental parameters determined were k (0.079 ± 0.008 h ‐1 ), t 1/2 (9.0 ± 2.9 h), V d / F (330.5 ± 87.3 L), Cl / F (38.2 ± 9.8 L/h) and AUC 0→∞ (1402.5 ± 404.7 ng.h/mL). The compartmental analysis was described appropriately using a two‐compartment body model, with first order absorption from two different sites in the gut. The parameters determined were k 21 (0.68 ± 0.2 h ‐1 ), k a1 (0.7 ± 0.27 h ‐1 ), k a2 (2.7 ± 1.8 h ‐1 ), V c / F (45.1 ± 15.7 L), α (33.3 ± 1.5 h ‐1 ), β (0.11 ± 0.03 h ‐1 ) and time for the beginning of the absorption from the second site (4.4 ± 2.1 h).

Conclusion

The developed analytical method was suitable for use in pharmacokinetic studies and therapeutic drug monitoring implementation. Sulpiride was well tolerated by the patients without any serious adverse events being observed. The double peaks in the serum concentration–time profiles could be due to differential rates of absorption along the gastrointestinal tract. The discontinuous absorption model with two sites of absorption was adequate to describe the double‐peak of the sulpiride plasma profile. ClinicalTrials. gov identifiers: NCT01777685. Copyright © 2013 John Wiley & Sons, Ltd.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulpirideAbsorptionAdministration, OralAdultBiological AvailabilityBiopharmaceuticsChromatography, High Pressure LiquidComparative Effectiveness ResearchDopamine AntagonistsDrug MonitoringFemaleHealthy VolunteersHumansMalePharmacovigilanceTime Factors

Stichwörter der Autor:innen

compartmental analysisdouble-peak plasma profilepharmacokineticssulpiridetherapeutic drug monitoring

Substanzen

Dopamine AntagonistsSulpiride

Autor:innen und Institutionen

  • Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt. Sallyhelmy@yahoo.com

Zitieren

APA

Helmy, S. A. (2013). Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double‐peak absorption profile after oral administration to human volunteers. Biopharmaceutics & Drug Disposition, 34(5), 288-301. https://doi.org/10.1002/bdd.1843

Vancouver

Helmy SA. Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double‐peak absorption profile after oral administration to human volunteers. Biopharmaceutics & Drug Disposition. 2013;34(5):288-301. doi:10.1002/bdd.1843

BibTeX
@article{Helmy2013,
  author = {Helmy, Sally A},
  title = {Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double‐peak absorption profile after oral administration to human volunteers},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2013},
  volume = {34},
  number = {5},
  pages = {288--301},
  doi = {10.1002/bdd.1843}
}
Kostenlos starten →